Phaseline

Companies › AO GENERIUM

AO GENERIUM: clinical trials, targets and expected readouts

3 active drug programs in 3 registered trials: 1 Phase 3, 1 Phase 2, 1 Phase 1; Neurology, Ophthalmology; next expected readout Dec 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
GNR-139
Aflibercept biosimilar; VEGF-A and PlGF antagonist; binds VEGFR1 and VEGFR2
FLT1, KDR, FLT4Phase 3nAMDMay 2028
GNR-055
Iduronate-2-sulfatase (I2S) enzyme replacement therapy
–Phase 2Mucopolysaccharidosis Type IIDec 2027
GNR-097
AAV9-delivered truncated dystrophin gene therapy (micro-dystrophin)
DMDPhase 1Duchenne Muscular DystrophyAug 2029

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT05208281GNR-055Phase 2Mucopolysaccharidosis Type IINeurologyDec 2027
NCT07844148GNR-139Phase 3nAMDOphthalmologyMay 2028
NCT07673809GNR-097Phase 1Duchenne Muscular DystrophyNeurologyAug 2029

Targets

FLT1 (1) KDR (1) FLT4 (1) DMD (1)

Companies with the same targets

Hutchmed Merck & Co. (MSD) Takeda Chipscreen Biosciences Avalyn Pharma Mannkind Ocular Therapeutix Betta Pharmaceuticals Criterium Chia Tai Tianqing Pharmaceutical Group

Companies built like this

NS Pharma Nippon Shinyaku Avidity Biosciences Sarepta Therapeutics Elpida Therapeutics SPC

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.